Nobody Wanted $HIMS at $15，Everyone Wants It at $35

When $Hims & Hers Health Inc.(HIMS)$ stock dropped to under $15 early this year the company was reviled for being untrustworthy and a one-trick pony in compounded GLP-1s.

Those times of panic were an opportunity for long-term investors to understand the strategy and why AndrewDudum would do seemingly crazy things that upset Big Pharma.

That’s what the two articles I wrote in those moments explained.

But few went through the exercise of understanding Hims strategy or what the potential outcomes of a patent lawsuit really was.

For those of you who read Asymmetric Investing in those brutal months and stayed invested or doubled down (like I did in the Asymmetric Portfolio) its days like this that show why research and conviction matter. Drowning out the short-term noise is hard, but necessary.

I’m not selling today, but I’m watching the conversation change in real time. People hated HIMS at $15 but love it at $35.

Stock price drives sentiment. But the biggest gains are made when sentiment is bad and the market is wrong.

Congratulations to the longs.

Job’s not done.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

131

2

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":576754180170952,"tweetId":"576754180170952","gmtCreate":1781833988575,"gmtModify":1781834443715,"author":{"id":4159952822702602,"idStr":"4159952822702602","authorId":4159952822702602,"authorIdStr":"4159952822702602","name":"Travis Hoium","avatar":"https://community-static.tradeup.com/news/7f6caf1342339cc5b5ecd9bf6ff43d46","vip":8,"userType":8,"introduction":"Passionate about helping people find life-changing long-term investments.\n","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":992,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://community-static.tradeup.com/news/cfbaa030219ca1cb472f16820fadeb54","width":"680","height":"383"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/cfbaa030219ca1cb472f16820fadeb54","width":"680","height":"383"}],"title":"Nobody Wanted $HIMS at $15，Everyone Wants It at $35","html":"<html><head></head><body><p>When <a data-mention-id=\"HIMS\" class=\"teditor-mention\" data-mention-name=\"Hims &amp; Hers Health Inc.\" href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$</a> stock dropped to under $15 early this year the company was reviled for being untrustworthy and a one-trick pony in compounded GLP-1s.</p>\n<p>Those times of panic were an opportunity for long-term investors to understand the strategy and why AndrewDudum would do seemingly crazy things that upset Big Pharma.</p>\n<p>That’s what the two articles I wrote in those moments explained.</p>\n<p>But few went through the exercise of understanding Hims strategy or what the potential outcomes of a patent lawsuit really was.</p>\n<p>For those of you who read Asymmetric Investing in those brutal months and stayed invested or doubled down (like I did in the Asymmetric Portfolio) its days like this that show why research and conviction matter. Drowning out the short-term noise is hard, but necessary.</p>\n<p>I’m not selling today, but I’m watching the conversation change in real time. People hated HIMS at $15 but love it at $35.</p>\n<p>Stock price drives sentiment. But the biggest gains are made when sentiment is bad and the market is wrong.</p>\n<p>Congratulations to the longs.</p>\n<p>Job’s not done.</p>\n<p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/cfbaa030219ca1cb472f16820fadeb54\" tg-width=\"680\" tg-height=\"383\"></p></body></html>","htmlText":"<html><head></head><body><p>When <a data-mention-id=\"HIMS\" class=\"teditor-mention\" data-mention-name=\"Hims &amp; Hers Health Inc.\" href=\"https://ttm.financial/S/HIMS\">$Hims &amp; Hers Health Inc.(HIMS)$</a> stock dropped to under $15 early this year the company was reviled for being untrustworthy and a one-trick pony in compounded GLP-1s.</p>\n<p>Those times of panic were an opportunity for long-term investors to understand the strategy and why AndrewDudum would do seemingly crazy things that upset Big Pharma.</p>\n<p>That’s what the two articles I wrote in those moments explained.</p>\n<p>But few went through the exercise of understanding Hims strategy or what the potential outcomes of a patent lawsuit really was.</p>\n<p>For those of you who read Asymmetric Investing in those brutal months and stayed invested or doubled down (like I did in the Asymmetric Portfolio) its days like this that show why research and conviction matter. Drowning out the short-term noise is hard, but necessary.</p>\n<p>I’m not selling today, but I’m watching the conversation change in real time. People hated HIMS at $15 but love it at $35.</p>\n<p>Stock price drives sentiment. But the biggest gains are made when sentiment is bad and the market is wrong.</p>\n<p>Congratulations to the longs.</p>\n<p>Job’s not done.</p>\n<p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/cfbaa030219ca1cb472f16820fadeb54\" tg-width=\"680\" tg-height=\"383\"></p></body></html>","text":"When $Hims & Hers Health Inc.(HIMS)$ stock dropped to under $15 early this year the company was reviled for being untrustworthy and a one-trick pony in compounded GLP-1s. Those times of panic were an opportunity for long-term investors to understand the strategy and why AndrewDudum would do seemingly crazy things that upset Big Pharma. That’s what the two articles I wrote in those moments explained. But few went through the exercise of understanding Hims strategy or what the potential outcomes of a patent lawsuit really was. For those of you who read Asymmetric Investing in those brutal months and stayed invested or doubled down (like I did in the Asymmetric Portfolio) its days like this that show why research and conviction matter. Drowning out the short-term noise is hard, but necessary. I’m not selling today, but I’m watching the conversation change in real time. People hated HIMS at $15 but love it at $35. Stock price drives sentiment. But the biggest gains are made when sentiment is bad and the market is wrong. Congratulations to the longs. Job’s not done.","highlighted":1,"essential":1,"paper":2,"likeSize":131,"commentSize":0,"repostSize":2,"favoriteSize":0,"link":"https://ttm.financial/post/576754180170952","repostId":0,"isVote":1,"tweetType":1,"viewCount":703,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["HIMS"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":true,"length":898,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/576754180170952"}